CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 10 enrolled
Drug / intervention
Pregabalin 300mgdrug
Likely dose
Pregabalin 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03927781
NCT03927781Phase 3Completed
CompareCT.gov

Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot

University of Missouri-Columbia·interventional·Posted Apr 25, 2019·Updated Apr 19, 2021

In Brief

A Phase 3 clinical trial evaluating Pregabalin 300mg for Nephrolithiasis and 7 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The investigators propose a pilot clinical trial on the use of perioperative pregabalin in order to decrease ureteral stent related symptoms and decrease opioid usage after ureteroscopy with stent placement. Patients undergoing ureteroscopy with stent placement will receive a single dose of 300 mg pregabalin PO in the preoperative area. This work will assess safety and feasibility of studying this regimen at our institution, with the aim of performing a randomized, placebo-controlled, double-blinded study in the future.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNephrolithiasis, Urolithiasis, Perioperative/Postoperative Complications, Pain, Postoperative, Pain, Acute, Anesthesia, Urologic Diseases, Anesthesia Morbidity
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2020202120222023202420252026
First PostedApr 25, 2019
Enrollment StartApr 1, 2019
Primary CompletionOct 17, 2019
Study CompletionOct 17, 2020
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.2 years ago

Interventions

Pregabalin 300mgdrug

One 300mg capsule will be administered PO 1 hour before surgery